Fig. 8

USP13 elevates MYC expression in lung cancer, contributing to the elevation of LUSC features. A MYC expression during cancer progression in KP and KPU mice following Ad5-SPC-Cre (left) or CC10-Cre (right) infection. Hyperplasia (arrow) and carcinoma in situ (CIS) (dotted line) are indicated. Scale bar = 50 µm. B IHC quantification for the portion of MYC⁺ cells in the lesions. Each dot represents one tumor nodule. Error bars indicate mean ± SEM. Two-tailed unpaired t-tests, ns = not significant, ****p < 0.0001. C Western blot of USP13, MYC, SOX2, p40, and β-actin on mouse KP cell line expressing exogenous USP13 or MYC. D Western blot showing USP13, MYC, SOX2, p40, CK5, and β-actin in human LUAD cell lines expressing exogenous USP13 or MYC. E Western blot of USP13, MYC, SOX2, and β-actin in H441 cells with knockdown of MYC using siRNA followed by transfected with mock or USP13. F Western blot of USP13, MYC, SOX2, and β-actin in H441 cells treated with either DMSO or 10 μM of 10058-F4 (MYC inhibitor) for 24 h followed by transfection with mock or USP13. G Schematic showing the proposed model of how USP13 promotes LUSC tumorigenesis in club cells